cell therapy also called cellular therapy cell transplantation cytotherapy therapy viable cells injected grafted implanted patient order effectuate medicinal example transplanting tcells capable fighting cancer cells via cellmediated immunity course immunotherapy grafting stem cells regenerate diseased tissues cell therapy originated nineteenth century scientists experimented injecting animal material attempt prevent treat although attempts produced positive benefit research found mid twentieth century human cells could used help prevent human body rejecting transplanted organs leading time successful bone marrow transplantation become common practice treatment patients compromised bone marrow disease infection radiation recent decades however stem cell cell transplantation gained significant interest researchers potential new therapeutic strategy wide range diseases particular degenerative immunogenic pathologies cell therapy defined therapy cellular material injected otherwise transplanted origins cell therapy perhaps traced nineteenth century charlesédouard brownséquard injected animal testicle extracts attempt stop effects paul niehans called inventor cell therapy attempted cure patient injecting material calf niehans claimed treated many people cancer using technique though claims never validated researchers found laboratory animals could helped reject organ transplants preinoculating cells donor animals minnesota first successful human bone marrow transplantation took recent work cell encapsulation pursued means shield therapeutic cells host immune response recent work includes microencapsulating cells gel core surrounded solid permeable bone marrow transplants common well established cell transplantation therapies first recording successful bone marrow transplant dates back dr e donnall thomas treated leukemia patient twinsiblings bone general patients presenting damaged destroyed bone marrow example chemotherapy andor radiation acute myeloid leukemia aml bone marrow derived cells infused patients blood stream injected cells able home affected bone marrow integrate proliferate recover reestablish biological function eg haematopoiesis annually estimated patients require potentially lifesaving bone marrow transplants long time bone marrow transplantation clinically applicable method cell transplantation however since cell therapy investigated wide scale pathologies disorders cell therapy provided novel approach effectuate therapeutic efficacy previously medical agents could effective directing inducing patients cells however many diseases disorders cell compromised eg senescence limited blood supply ischemia inflammation simply reduction number cells cell therapy offers new strategy supports introduction new active cells restore previously compromised deteriorated tissue organ structures recent times cell therapy recognized important field treatment human investigations ongoing articular brain etc consequence cell therapy strategy attracting significant investments commercial entities suggest strong prospects future atara biotherapeutics became first ever allogeneic cell therapy company reviewed regulatory agency world ema cell therapy targeted many clinical indications multiple organs several modes cell delivery accordingly specific mechanisms action involved therapies wideranging however two main principles cells facilitate therapeutic action allogeneic cell therapy donor different person recipient pharmaceutical manufacturing allogenic methodology promising unmatched allogenic therapies form basis shelf research interest attempting develop products treat conditions including crohns variety vascular autologous cell therapy cells transplanted derived patients tissues multiple clinical studies ongoing obtain stromal cells bonemarrow adipose tissue peripheral blood transplanted sites injury stress actively explored eg repair could also involve isolation matured cells diseased tissues later reimplanted neighboring tissues strategy assessed clinical trials eg spine preventing disc reherniation adjacent disc benefit autologous strategy limited concern immunogenic responses transplant rejection nevertheless autologous strategy often costly due patientbypatient processing thus preventing option create large qualitycontrolled batches moreover autologous strategies generally allow product quality effectiveness testing prior transplantation highly donor thus patient dependent particular concern often patient functioning donor diseased impact cell potency quality xenogeneic cell therapies recipient receive cells another species example transplantation pig derived cells humans currently xenogeneic cell therapies primarily involve human cell transplantation experimental animal models assessment efficacy however future advances could potentially enable xenogeneic strategies humans research human embryonic stem cells controversial regulation varies country country countries banning outright nevertheless cells investigated basis number therapeutic applications including possible treatments parkinsons neural stem cells nscs subject ongoing research possible therapeutic applications example treating number neurological disorders parkinsons disease huntingtons mscs immunomodulatory multipotent fast proliferating unique capabilities mean used wide range treatments including immunemodulatory therapy bone cartilage regeneration myocardium regeneration treatment hurler syndrome skeletal neurological researchers demonstrated use mscs treatment osteogenesis imperfecta oi horwitz et al transplanted bone marrow bm cells human leukocyte antigen hlaidentical siblings patients oi results show mscs develop normal osteoblasts leading fast bone development reduced fracture recent clinical trial showed allogeneic fetal mscs transplanted utero patients severe oi engraft differentiate bone human besides bone cartilage regeneration cardiomyocyte regeneration autologous bm mscs also reported recently introduction bm mscs following myocardial infarction mi resulted significant reduction damaged regions improvement heart function clinical trials treatment acute mi prochymal osiris therapeutics underway also clinical trial revealed huge improvements nerve conduction velocities hurlers syndrome patients infused bm mscs hlaidentical hematopoietic stem cells hscs derived bone marrow blood cells abilities selfrenew differentiate types blood cells especially involved human immune system thus used treat blood immune disorders since human bone marrow grafting first published significant advancements hscs therapy following syngeneic marrow allogeneic marrow performed successfully hscs therapy also render cure reconstituting damaged bloodforming cells restoring immune system highdose chemotherapy eliminate three types hsc transplantation syngeneic autologous allogeneic syngeneic transplantations occur identical twins autologous transplantations use hscs obtained directly patient hence avoid complications tissue incompatibility whereas allogeneic transplantations involve use donor hscs either genetically related unrelated recipient lower risks transplant include graft rejection graftversushost disease gvhd allogeneic hsct must satisfy compatibility hla loci ie genetic matching reduce immunogenicity transplant addition bone marrowderived hscs use alternative sources umbilical cord blood ucb peripheral blood stem cells pbscs increasing comparison bone marrowderived hsc recipients pbsc recipients myeloid malignancies reported faster engraftment better overall use ucb requires less stringent hla loci matching although time engraftment longer graft failure rate alternative stem progenitor cells investigations exploring transplantation differentiated cells possess low proliferation ability tends involve specialized cells able facilitate specific function patients body example transplantation repair heart function islet cell establishing insulin homeostasis diabetes patients supportregenerate extracellular matrix production specific tissues example intervertebral disc repair transplanting alternative medicine cell therapy defined injection nonhuman cellular animal material attempt treat quackwatch labels senseless since cells organs one species replace cells organs species number serious adverse effects alternative animalbased form cell therapy american cancer society say available scientific evidence support claims cell therapy effective treating cancer disease may fact lethal despite one fast growing areas within life manufacturing cell therapy products largely hindered small scale batches labourintensive number manufacturers turning automated methods production eliminating human involvement risk human error automated methods cell therapy manufacturing opened larger scale production higher quality products lower logistics departments biopharma companies experience new obstacles introduction new cell gene therapy products car tcell therapies allogeneic therapies cell gene therapies require manufacturer distributors alike implement new systems processes order ensure safe handling delivery additionally ondemand inventory therefore becomes important especially regard unforeseeable events like pandemic supply chain interruptions furthermore recent changes result covid pandemic political instability europe secondary brexit impacted logistics chain cellular therapies httpsenwikipediaorgwikicelltherapy